Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Ladenstein R, Pötschger U, Valteau-Couanet D. et al.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Lancet Oncol 2018;
19 (12) 1617-1629

Bibliographische Angaben herunterladen

Aufrufen in: